• Laekna disclosed completed Phase I trial results for LAE103 in overweight or obese participants in Australia on November 9, 2026.
• A single injection was well tolerated, with no serious adverse events or treatment discontinuations due to adverse events.
• Results supported once-monthly injections, with observed biological effects consistent with expectations.
• Development is being accelerated for sarcopenic obesity and other muscle-related diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laekna Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261109-12404912), on November 09, 2026, and is solely responsible for the information contained therein.